Literature DB >> 11603220

Cellular apoptosis susceptibility gene expression in endometrial carcinoma: correlation with Bcl-2, Bax, and caspase-3 expression and outcome.

G Peiró1, J Diebold, G B Baretton, R Kimmig, U Löhrs.   

Abstract

Deregulation of proliferation and apoptosis is known to contribute to neoplastic transformation and growth. Using specific antibodies for the cellular apoptosis susceptibility (CAS) gene, caspase-3, Bcl-2, and Bax, we examined the protein expression in 89 endometrial carcinomas and in 56 samples of nonneoplastic adjacent endometrium for comparison. Immunostaining results were scored with regard to approximate percentage of positive tumor cells (< 10%, 10% to 50%, > 50%) and relative immunostaining intensity (1+, 2+, 3+). In nonneoplastic endometrium, CAS protein was expressed in 70.6%, Bax in 64%, caspase-3 in 52%, and Bcl-2 in 87%. In neoplastic tissue, CAS was present in 93% of the tumors, Bax in 88%, caspase-3 in 77%, and Bcl-2 in 51%. Bcl-2:Bax ratio was > 1 in 9 cases (10%). In cases of atrophy (n = 24) and simple (n = 10) and complex (n = 22) hyperplasia in the adjacent endometrium, lower levels of expression compared with carcinoma were observed for CAS (p = 0.003), caspase-3 (p = 0.034), and Bax (p = 0.04) and higher levels for Bcl-2, although for this protein the results were not statistically significant (p = 0.32). There was no association between immunoscores and FIGO stage. High caspase-3 levels were seen in endometrioid tumor type (p = 0.017). CAS expression was higher in grade 3 tumors (p = 0.002) and older patients (p = 0.013). All tumors of younger patients (< 50 years) were Bcl-2 negative (p = 0.037). Caspase-3 correlated positively with CAS (p = 0.008), Bax (p = 0.04), and low Bcl-2:Bax ratio (p = 0.043), and inversely (as a trend) with Bcl-2 (p = 0.056). Survival analysis (Kaplan-Meier and Cox regression) established a strong association between prognosis and stage, grade, and histologic type (all p < or = 0.0036). In addition, shorter survival was observed for patients whose tumors contained > 50% of positive cells for caspase-3 (p = 0.024) or for CAS (p = 0.04). Age, Bcl-2, Bax, and Bcl-2:Bax ratio did not provide prognostic information. Our results suggest a role of CAS, Bcl-2, Bax, and caspase-3, which are apparently involved in the progressive deregulation of proliferation and apoptosis leading from simple and complex hyperplasia to carcinoma. In addition, CAS and caspase-3 protein levels may be useful markers in predicting the outcome of the patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11603220     DOI: 10.1097/00004347-200110000-00008

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  16 in total

1.  Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.

Authors:  Kristen Upson; Kimberly H Allison; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Elizabeth M Swisher; Jennifer A Doherty; Rochelle L Garcia
Journal:  Am J Obstet Gynecol       Date:  2012-05-16       Impact factor: 8.661

Review 2.  CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy.

Authors:  Ming-Chung Jiang
Journal:  Tumour Biol       Date:  2016-09-05

3.  CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression.

Authors:  Anke H Sillars-Hardebol; Beatriz Carvalho; Jeroen A M Beliën; Meike de Wit; Pien M Delis-van Diemen; Marianne Tijssen; Mark A van de Wiel; Fredrik Pontén; Gerrit A Meijer; Remond J A Fijneman
Journal:  Cell Oncol (Dordr)       Date:  2012-06-19       Impact factor: 6.730

4.  Expression of caspase-3 predicts prognosis in advanced noncardia gastric cancer.

Authors:  Sousana Amptoulach; Andreas C Lazaris; Ioanna Giannopoulou; Nikolaos Kavantzas; Efstratios Patsouris; Nikolaos Tsavaris
Journal:  Med Oncol       Date:  2014-12-05       Impact factor: 3.064

Review 5.  Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug-induced apoptosis.

Authors:  Cheng-Jeng Tai; Chung-Huei Hsu; Shing-Chuan Shen; Woan-Ruoh Lee; Ming-Chung Jiang
Journal:  J Exp Clin Cancer Res       Date:  2010-08-11

6.  Network Pharmacology-Based and Molecular Docking Analysis of Resveratrol's Pharmacological Effects on Type I Endometrial Cancer.

Authors:  Zixing Zhong; Xin Guo; Yanmei Zheng
Journal:  Anticancer Agents Med Chem       Date:  2022       Impact factor: 2.527

7.  Association of genetic markers in the BCL-2 family of apoptosis-related genes with endometrial cancer risk in a Chinese population.

Authors:  Tsogzolmaa Dorjgochoo; Yong-Bing Xiang; Jirong Long; Jiajun Shi; Sandra Deming; Wang-Hong Xu; Hui Cai; Jiarong Cheng; Qiuyin Cai; Wei Zheng; Xiao-Ou Shu
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

8.  Correlations between cytoplasmic CSE1L in neoplastic colorectal glands and depth of tumor penetration and cancer stage.

Authors:  Cheng-Jeng Tai; Tzu-Cheng Su; Ming-Chung Jiang; Hung-Chang Chen; Shing-Chuan Shen; Woan-Ruoh Lee; Ching-Fong Liao; Ying-Chun Chen; Shu-Hui Lin; Li-Tzu Li; Ko-Hung Shen; Chung-Min Yeh; Kun-Tu Yeh; Ching-Hsiao Lee; Hsin-Yi Shih; Chun-Chao Chang
Journal:  J Transl Med       Date:  2013-01-31       Impact factor: 5.531

9.  Immunohistochemical features of a papillary squamous cell carcinoma of the endometrium with transitional cell differentiation.

Authors:  Alfredo Ribeiro-Silva
Journal:  Diagn Pathol       Date:  2007-07-23       Impact factor: 2.644

10.  CSE1L/CAS, the cellular apoptosis susceptibility protein, enhances invasion and metastasis but not proliferation of cancer cells.

Authors:  Ching-Fong Liao; Shue-Fen Luo; Li-Tzu Li; Chuang-Yu Lin; Ying-Chun Chen; Ming-Chung Jiang
Journal:  J Exp Clin Cancer Res       Date:  2008-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.